Exendin-9,39 and Satiety After Bariatric Surgery
| Status: | Recruiting |
|---|---|
| Conditions: | Obesity Weight Loss |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 20 - 70 |
| Updated: | 1/10/2019 |
| Start Date: | June 2016 |
| End Date: | December 2019 |
| Contact: | Paula D Giesler, RN, BSN, CDE |
| Email: | giesler.paula@mayo.edu |
| Phone: | 507-255-8345 |
The overall aim of the application is to determine the contribution of the elevated incretin
hormone concentrations seen after certain types of bariatric surgery to the regulation of
food intake and satiety.
hormone concentrations seen after certain types of bariatric surgery to the regulation of
food intake and satiety.
Both Sleeve Gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB) increase GLP-1
concentrations, although this is of lesser magnitude in SG compared to RYGB. Data suggests
that endogenous GLP-1 is at least partially responsible for reducing free-choice caloric
intake after RYGB, providing a mechanism underlying differences between procedures.
Inhibition of GLP-1 action with Exendin-9,39 after RYGB accelerates gastric emptying. These
observations suggest that factors other than anatomy regulate the upper gastrointestinal
response to food ingestion. It is therefore reasonable to consider that the postprandial rise
in GLP-1 might affect feeding behavior after RYGB, and to a lesser extent SG, where the
increase in GLP-1 is less marked.
concentrations, although this is of lesser magnitude in SG compared to RYGB. Data suggests
that endogenous GLP-1 is at least partially responsible for reducing free-choice caloric
intake after RYGB, providing a mechanism underlying differences between procedures.
Inhibition of GLP-1 action with Exendin-9,39 after RYGB accelerates gastric emptying. These
observations suggest that factors other than anatomy regulate the upper gastrointestinal
response to food ingestion. It is therefore reasonable to consider that the postprandial rise
in GLP-1 might affect feeding behavior after RYGB, and to a lesser extent SG, where the
increase in GLP-1 is less marked.
Inclusion Criteria:
- Undergone either sleeve gastrectomy or Roux-en-Y Gastric Bypass surgery within prior 2
years
- Healthy, with no active systemic illness
Exclusion Criteria:
- Pregnancy
- Functional or organic bowel symptoms
- Systemic illness
- Diabetes
- Bariatric surgery > 2 years
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
